{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:09:09Z","timestamp":1791544149979,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Functional tests for lupus anticoagulants (LA) as part of a thrombophilia workup are commonly performed in patients under anticoagulant therapy that may interfere with assay results. There is no consensus on how these tests should be assessed in patients on direct oral anticoagulants (DOACs). In this retrospective cohort study, we analysed data from patients with a history of thrombosis in whom dilute Russell viper venom time (dRVVT), LA-sensitive aPTT, and solid phase assays for antiphospholipid antibodies (aPL) were performed (n\u2009=\u20093,147, thereof 588 on rivaroxaban, 144 on apixaban, 1,179 on other anticoagulant drugs). The dRVVT ratio was correlated with rivaroxaban (r\u2009=\u20090.30, <jats:italic>P<\/jats:italic>\u2009&lt;\u200910<jats:sup>\u20134<\/jats:sup>) but not with apixaban plasma levels. The LA-sensitive aPTT\/aPTT ratio showed no correlation with DOAC levels. Correspondingly, the rate of patients with abnormal dRVVT test was significantly higher (<jats:italic>P<\/jats:italic>\u2009&lt;\u200910<jats:sup>\u20134<\/jats:sup>) under rivaroxaban (88%) than in thrombosis patients without anticoagulant medication (6%), independent from their aPL plasma levels. No isolated positive results of functional LA testing in patients on anticoagulants could be confirmed in repeated testing after discontinuation of the medication (n\u2009=\u200940). These data indicate that rivaroxaban should be discontinued before functional LA testing is performed. However, viable interpretation of these tests appears to be less affected in patients on apixaban.<\/jats:p>","DOI":"10.1038\/s41598-020-69199-1","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T10:07:35Z","timestamp":1595412455000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Functional lupus anticoagulant testing in a large retrospective cohort of thrombosis patients with direct oral anticoagulants"],"prefix":"10.1038","volume":"10","author":[{"given":"Sara","family":"Reda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Br\u00fcgelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"P\u00f6tzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"R\u00fchl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,22]]},"reference":[{"key":"69199_CR1","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.blre.2017.07.006","volume":"31","author":"S Chaturvedi","year":"2017","unstructured":"Chaturvedi, S. & McCrae, K. R. Diagnosis and management of the antiphospholipid syndrome. Blood Rev. 31, 406\u2013417 (2017).","journal-title":"Blood Rev."},{"key":"69199_CR2","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1002\/acr.22066","volume":"65","author":"L Andreoli","year":"2013","unstructured":"Andreoli, L. et al. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: A critical review of the literature. Arthritis Care Res. 65, 1869\u20131873 (2013).","journal-title":"Arthritis Care Res."},{"key":"69199_CR3","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMra1700365","volume":"377","author":"JM Connors","year":"2017","unstructured":"Connors, J. M. Thrombophilia testing and venous thrombosis. N. Engl. J. Med. 377, 1177\u20131187 (2017).","journal-title":"N. Engl. J. Med."},{"key":"69199_CR4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"S Miyakis","year":"2006","unstructured":"Miyakis, S. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4, 295\u2013306 (2006).","journal-title":"J. Thromb. Haemost."},{"key":"69199_CR5","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F","volume":"42","author":"WA Wilson","year":"1999","unstructured":"Wilson, W. A. et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum. 42, 1309\u20131311 (1999).","journal-title":"Arthritis Rheum."},{"key":"69199_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1055\/s-0033-1364185","volume":"40","author":"GW Moore","year":"2014","unstructured":"Moore, G. W. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. Semin. Thromb. Haemost. 40, 163\u2013171 (2014).","journal-title":"Semin. Thromb. Haemost."},{"key":"69199_CR7","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1182\/blood-2002-02-0441","volume":"101","author":"M Galli","year":"2003","unstructured":"Galli, M., Luciani, D., Bertolini, G. & Barbui, T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: A systematic review of the literature. Blood 101, 1827\u20131832 (2003).","journal-title":"Blood"},{"key":"69199_CR8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000083810","volume":"33","author":"M Galli","year":"2003","unstructured":"Galli, M. Antiphospholipid syndrome: Association between laboratory tests and clinical practice. Pathophysiol. Haemost. Thromb. 33, 249\u2013255 (2003).","journal-title":"Pathophysiol. Haemost. Thromb."},{"key":"69199_CR9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1160\/TH06-05-0287","volume":"96","author":"A Ruffatti","year":"2006","unstructured":"Ruffatti, A. et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb. Haemost. 96, 337\u2013341 (2006).","journal-title":"Thromb. Haemost."},{"key":"69199_CR10","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/sj.thj.6200206","volume":"4","author":"M Galli","year":"2003","unstructured":"Galli, M. & Barbui, T. Antiphospholipid antibodies and thrombosis: Strength of association. Hematol. J. 4, 180\u2013186 (2003).","journal-title":"Hematol. J."},{"key":"69199_CR11","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1055\/s-0038-1649901","volume":"74","author":"JT Brandt","year":"1995","unstructured":"Brandt, J. T., Triplett, D. A., Alving, B. & Scharrer, I. Criteria for the diagnosis of lupus anticoagulants: An update. On behalf of the Subcomittee on Lupus Anticoagulant\/Antiphospholipid Antibody of the Scientific and Standardisation of the ISTH. Thromb. Haemost. 74, 1185\u20131190 (1995).","journal-title":"Thromb. Haemost."},{"key":"69199_CR12","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1111\/j.1538-7836.2009.03555.x","volume":"7","author":"V Pengo","year":"2009","unstructured":"Pengo, V. et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the Internation Society on Thrombosis and Haemostasis. J. Thromb. Haemost. 7, 1737\u20131740 (2009).","journal-title":"J. Thromb. Haemost."},{"key":"69199_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1365-2141.2012.09037.x","volume":"157","author":"D Keeling","year":"2012","unstructured":"Keeling, D. et al. Guidelines on the investigation and management of antiphospholipid syndrome. Br. J. Haematol. 157, 47\u201358 (2012).","journal-title":"Br. J. Haematol."},{"key":"69199_CR14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1160\/TH10-08-0511","volume":"105","author":"E Merriman","year":"2011","unstructured":"Merriman, E. et al. Rivaroxaban and false positive lupus anticoagulant testing. Thromb. Haemost. 105, 385\u2013386 (2011).","journal-title":"Thromb. Haemost."},{"key":"69199_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1160\/TH12-04-0228","volume":"109","author":"H Mani","year":"2013","unstructured":"Mani, H., Hesse, C., Stratmann, G. & Lindhoff-Last, E. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb. Haemost. 109, 127\u2013136 (2013).","journal-title":"Thromb. Haemost."},{"key":"69199_CR16","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1111\/j.1538-7836.2011.04395.x","volume":"9","author":"GM van Os","year":"2011","unstructured":"van Os, G. M., de Laat, B., Kamphuisen, P. W., Meijers, J. C. & de Groot, P. G. Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. J. Thromb. Haemost. 9, 1657\u20131659 (2011).","journal-title":"J. Thromb. Haemost."},{"key":"69199_CR17","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.pathol.2015.11.025","volume":"48","author":"R Bonar","year":"2016","unstructured":"Bonar, R. et al. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: A comprehensive assessment using in vitro and ex vivo samples. Pathology 48, 60\u201371 (2016).","journal-title":"Pathology"},{"key":"69199_CR18","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/PAT.0000000000000252","volume":"47","author":"R Bonar","year":"2015","unstructured":"Bonar, R. et al. The effect of dabigatran on haemostasis tests: A comprehensive assessment using in vitro and ex vivo samples. Pathology 47, 355\u2013364 (2015).","journal-title":"Pathology"},{"key":"69199_CR19","first-page":"1264","volume":"13","author":"T G\u00f3ralczyk","year":"2015","unstructured":"G\u00f3ralczyk, T., Iwaniec, T., Wypasek, E. & Undas, A. False-positive lupus anticoagulant in patients receiving rivaroxaban: 24 h since the last dose are needed to exclude antiphospholipid syndrome. Blood Coagul. Fibrinolysis 13, 1264\u20131273 (2015).","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"69199_CR20","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/ijlh.12138","volume":"36","author":"ME Martinuzzo","year":"2014","unstructured":"Martinuzzo, M. E. et al. Frequent false-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin. Int. J. Lab. Hematol. 36, 144\u2013150 (2014).","journal-title":"Int. J. Lab. Hematol."},{"key":"69199_CR21","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1111\/jth.12917","volume":"13","author":"DR Arachchillage","year":"2015","unstructured":"Arachchillage, D. R. et al. Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome. J. Thromb. Haemost. 13, 1264\u20131273 (2015).","journal-title":"J. Thromb. Haemost."},{"key":"69199_CR22","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1080\/00365513.2018.1522664","volume":"78","author":"A Hillarp","year":"2018","unstructured":"Hillarp, A. et al. Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays. Scand. J. Clin. Lab. Investig. 78, 575\u2013583 (2018).","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"69199_CR23","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1111\/jth.12649","volume":"12","author":"A Hillarp","year":"2014","unstructured":"Hillarp, A. et al. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays. J. Thromb. Haemost. 12, 1545\u20131553 (2014).","journal-title":"J. Thromb. Haemost."},{"key":"69199_CR24","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/jth.13912","volume":"16","author":"J Douxfils","year":"2018","unstructured":"Douxfils, J. et al. Laboratory testing in patients treated with direct oral anticoagulants: A practical guide for clinicians. J. Thromb. Haemost. 16, 209\u2013219 (2018).","journal-title":"J. Thromb. Haemost."},{"key":"69199_CR25","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1093\/labmed\/lmw029","volume":"47","author":"LM Murer","year":"2016","unstructured":"Murer, L. M., Pirruccello, S. J. & Koepsell, S. A. Rivaroxaban therapy, false-positive lupus anticoagulant screening results, and confirmatory assay results. Lab. Med. 47, 275\u2013278 (2016).","journal-title":"Lab. Med."},{"key":"69199_CR26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1160\/TH16-02-0081","volume":"116","author":"F Ratzinger","year":"2016","unstructured":"Ratzinger, F. et al. Lupus-anticoagulant testing at NOAC trough levels. Thromb. Haemost. 116, 235\u2013240 (2016).","journal-title":"Thromb. Haemost."},{"key":"69199_CR27","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1160\/TH17-03-0204","volume":"117","author":"A Antovic","year":"2017","unstructured":"Antovic, A. et al. Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting. Thromb. Haemost. 117, 1700\u20131704 (2017).","journal-title":"Thromb. Haemost."},{"key":"69199_CR28","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1055\/s-0038-1649507","volume":"2","author":"PY Kim","year":"2018","unstructured":"Kim, P. Y. et al. Mechanistic basis for the differential effects of rivaroxaban and apixaban on global tests of coagulation. T. H. Open 2, e190\u2013e201. https:\/\/doi.org\/10.1055\/s-0038-1649507 (2018).","journal-title":"T. H. Open"},{"key":"69199_CR29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1365-2141.1989.tb00242.x","volume":"73","author":"DA Triplett","year":"1989","unstructured":"Triplett, D. A. & Brandt, J. Laboratory identification of the lupus anticoagulant. Br. J. Haematol. 73, 139\u2013142 (1989).","journal-title":"Br. J. Haematol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69199-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69199-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69199-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T14:55:53Z","timestamp":1670338553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69199-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,22]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["69199"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-69199-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,22]]},"assertion":[{"value":"8 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12221"}}